Christmas arrived early! We are pleased to announce that RESPINOR has secured 14.2M NOKs in soft funding from the Research Council of Norway to perform our pivotal study (DE-RISK WF) which will commence in Q1-2021! This will take us one step further to secure that our breakthrough technology, RESPINOR DXT, will be available for critically ill patients on mechanical ventilation world wide.

Thank you to the Research Council of Norway for supporting innovation in Norway within MedTech!

https://www.forskningsradet.no/nyheter/2020/forskningsradet-investerer-602-millioner-kroner-i-mer-innovasjon-i-naringslivet/

‍